IDIOPATHIC THROMBOCYTOPENIC PURPURA : DESCRIPTIVE AND RETROSPECTIVE STUDY OF 151 PATIENTS
(Abstract release date: 05/19/16)
EHA Library. Haifa R. 06/09/16; 134984; PB2084
Dr. Regaieg Haifa
Contributions
Contributions
Abstract
Abstract: PB2084
Type: Publication Only
Background
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by a variable intensity of thrombocytopenia related to the presence of anti-platelet antibody originally of a destruction of platelets by the spleen macrophages associated with production Medullar quantitatively or qualitativement inadequate. The ITP treatment todate remains poorly standardized.
Aims
We report the results of a clinical study, biology and therapeutic study realized from 151 patients.
Methods
This is a retrospective and monocentric study of 151 patients with ITP (a platelet count <100 10 3 / mm 3) collected in the department of hematology hospital Farhat Hached Sousse over a period of 10 years (2004-2014).
Results
The data of 151 patients were included in our study. The average age was 40 years (15-85 years). The sex ratio was to 0.42 (m/f). The average rate of platelets at diagnosis was 20 000 G / L (0-50000). Thrombocytopenia was discovered incidentally in blood cell in 21.2% of cases. In addition 78.8% of patients experienced a hemorrhagic syndrome of varying intensity but not binding prognosis in any case. Eight percent of these patients received platelet concentrate transfusions because of active bleeding. A functional anemic syndrome was present in 17.8% of patients. Regarding treatment, corticosteroid was prescribed first line in 92.1% of cases and only 7.9% of patients received immunoglobulin. The response rate was 83.4% with an complete responce estimated at 62.9%. A relapse occurred in 29.8% of patients and ITP evolves to chronicity in 47% of cases. Only 3 patients (2%) were splenectomized with a normalization of the number of platelets in a patient. 23 patients (15.2%) received treatment with rituximab, the response rate was 39%. After a mean follow-up 38 months, only one death was occurred and it wasn’t related to PTI.
Conclusion
ITP is a rare disease that affects a middle aged population. It evaluate to a chronic mode, the prognosis is good and only a minority patient progresses to a severe form of the disease. Indeed, the rate of relapse or non-response is important and imposed using several therapeutic lines. Place of new treatments receptor agonists such as thrombopoietin (TPO) or new anti lymphocyte B therapies remain to be defined.
Session topic: E-poster
Keyword(s): Idiopathic thombocytopenic purpura (ITP)
Type: Publication Only
Background
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by a variable intensity of thrombocytopenia related to the presence of anti-platelet antibody originally of a destruction of platelets by the spleen macrophages associated with production Medullar quantitatively or qualitativement inadequate. The ITP treatment todate remains poorly standardized.
Aims
We report the results of a clinical study, biology and therapeutic study realized from 151 patients.
Methods
This is a retrospective and monocentric study of 151 patients with ITP (a platelet count <100 10 3 / mm 3) collected in the department of hematology hospital Farhat Hached Sousse over a period of 10 years (2004-2014).
Results
The data of 151 patients were included in our study. The average age was 40 years (15-85 years). The sex ratio was to 0.42 (m/f). The average rate of platelets at diagnosis was 20 000 G / L (0-50000). Thrombocytopenia was discovered incidentally in blood cell in 21.2% of cases. In addition 78.8% of patients experienced a hemorrhagic syndrome of varying intensity but not binding prognosis in any case. Eight percent of these patients received platelet concentrate transfusions because of active bleeding. A functional anemic syndrome was present in 17.8% of patients. Regarding treatment, corticosteroid was prescribed first line in 92.1% of cases and only 7.9% of patients received immunoglobulin. The response rate was 83.4% with an complete responce estimated at 62.9%. A relapse occurred in 29.8% of patients and ITP evolves to chronicity in 47% of cases. Only 3 patients (2%) were splenectomized with a normalization of the number of platelets in a patient. 23 patients (15.2%) received treatment with rituximab, the response rate was 39%. After a mean follow-up 38 months, only one death was occurred and it wasn’t related to PTI.
Conclusion
ITP is a rare disease that affects a middle aged population. It evaluate to a chronic mode, the prognosis is good and only a minority patient progresses to a severe form of the disease. Indeed, the rate of relapse or non-response is important and imposed using several therapeutic lines. Place of new treatments receptor agonists such as thrombopoietin (TPO) or new anti lymphocyte B therapies remain to be defined.
Session topic: E-poster
Keyword(s): Idiopathic thombocytopenic purpura (ITP)
Abstract: PB2084
Type: Publication Only
Background
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by a variable intensity of thrombocytopenia related to the presence of anti-platelet antibody originally of a destruction of platelets by the spleen macrophages associated with production Medullar quantitatively or qualitativement inadequate. The ITP treatment todate remains poorly standardized.
Aims
We report the results of a clinical study, biology and therapeutic study realized from 151 patients.
Methods
This is a retrospective and monocentric study of 151 patients with ITP (a platelet count <100 10 3 / mm 3) collected in the department of hematology hospital Farhat Hached Sousse over a period of 10 years (2004-2014).
Results
The data of 151 patients were included in our study. The average age was 40 years (15-85 years). The sex ratio was to 0.42 (m/f). The average rate of platelets at diagnosis was 20 000 G / L (0-50000). Thrombocytopenia was discovered incidentally in blood cell in 21.2% of cases. In addition 78.8% of patients experienced a hemorrhagic syndrome of varying intensity but not binding prognosis in any case. Eight percent of these patients received platelet concentrate transfusions because of active bleeding. A functional anemic syndrome was present in 17.8% of patients. Regarding treatment, corticosteroid was prescribed first line in 92.1% of cases and only 7.9% of patients received immunoglobulin. The response rate was 83.4% with an complete responce estimated at 62.9%. A relapse occurred in 29.8% of patients and ITP evolves to chronicity in 47% of cases. Only 3 patients (2%) were splenectomized with a normalization of the number of platelets in a patient. 23 patients (15.2%) received treatment with rituximab, the response rate was 39%. After a mean follow-up 38 months, only one death was occurred and it wasn’t related to PTI.
Conclusion
ITP is a rare disease that affects a middle aged population. It evaluate to a chronic mode, the prognosis is good and only a minority patient progresses to a severe form of the disease. Indeed, the rate of relapse or non-response is important and imposed using several therapeutic lines. Place of new treatments receptor agonists such as thrombopoietin (TPO) or new anti lymphocyte B therapies remain to be defined.
Session topic: E-poster
Keyword(s): Idiopathic thombocytopenic purpura (ITP)
Type: Publication Only
Background
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by a variable intensity of thrombocytopenia related to the presence of anti-platelet antibody originally of a destruction of platelets by the spleen macrophages associated with production Medullar quantitatively or qualitativement inadequate. The ITP treatment todate remains poorly standardized.
Aims
We report the results of a clinical study, biology and therapeutic study realized from 151 patients.
Methods
This is a retrospective and monocentric study of 151 patients with ITP (a platelet count <100 10 3 / mm 3) collected in the department of hematology hospital Farhat Hached Sousse over a period of 10 years (2004-2014).
Results
The data of 151 patients were included in our study. The average age was 40 years (15-85 years). The sex ratio was to 0.42 (m/f). The average rate of platelets at diagnosis was 20 000 G / L (0-50000). Thrombocytopenia was discovered incidentally in blood cell in 21.2% of cases. In addition 78.8% of patients experienced a hemorrhagic syndrome of varying intensity but not binding prognosis in any case. Eight percent of these patients received platelet concentrate transfusions because of active bleeding. A functional anemic syndrome was present in 17.8% of patients. Regarding treatment, corticosteroid was prescribed first line in 92.1% of cases and only 7.9% of patients received immunoglobulin. The response rate was 83.4% with an complete responce estimated at 62.9%. A relapse occurred in 29.8% of patients and ITP evolves to chronicity in 47% of cases. Only 3 patients (2%) were splenectomized with a normalization of the number of platelets in a patient. 23 patients (15.2%) received treatment with rituximab, the response rate was 39%. After a mean follow-up 38 months, only one death was occurred and it wasn’t related to PTI.
Conclusion
ITP is a rare disease that affects a middle aged population. It evaluate to a chronic mode, the prognosis is good and only a minority patient progresses to a severe form of the disease. Indeed, the rate of relapse or non-response is important and imposed using several therapeutic lines. Place of new treatments receptor agonists such as thrombopoietin (TPO) or new anti lymphocyte B therapies remain to be defined.
Session topic: E-poster
Keyword(s): Idiopathic thombocytopenic purpura (ITP)
{{ help_message }}
{{filter}}